Geneos Wealth Management Inc. Has $1.29 Million Holdings in Cencora, Inc. (NYSE:COR)

Geneos Wealth Management Inc. lowered its position in Cencora, Inc. (NYSE:COR) by 2.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,734 shares of the company’s stock after selling 124 shares during the period. Geneos Wealth Management Inc.’s holdings in Cencora were worth $1,288,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Concord Wealth Partners acquired a new position in Cencora in the third quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Cencora during the 3rd quarter valued at about $41,000. Modus Advisors LLC acquired a new stake in Cencora during the fourth quarter worth approximately $54,000. Finally, Carolina Wealth Advisors LLC grew its stake in Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after purchasing an additional 209 shares during the period. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Wells Fargo & Company decreased their price target on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, Mizuho initiated coverage on Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $277.00.

Cencora Stock Performance

Shares of Cencora stock opened at $248.45 on Monday. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The business has a 50 day moving average price of $237.51 and a 200-day moving average price of $234.83. The company has a market cap of $48.02 billion, a PE ratio of 33.08, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.89%. Cencora’s dividend payout ratio (DPR) is 29.29%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 in the last three months. 15.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.